期刊文献+

Association of Lysosome Associated Protein Transmembrane 4 Beta Gene Polymorphism with the Risk of Pancreatic Cancer 被引量:1

Association of Lysosome Associated Protein Transmembrane 4 Beta Gene Polymorphism with the Risk of Pancreatic Cancer
下载PDF
导出
摘要 Objective: Lysosome associated protein transmembrane 4 beta (LAPTM4B) was originally identified as a gene in human hepatocellular carcinoma (HCC). It was successfully cloned by fluorescence differential display, rapid amplification of cDNA ends (RACE) and reverse transcription polymerase chain reaction (RT-PCR). Previous study showed that the novel gene played an important role in the occurrence, development, migration and prognosis of tumors. Pancreatic cancer is an aggressive malignancy with the majority of patients dying within one year after diagnosis. This study tries to find out the relationship between lysosome associated protein transmembrane 4 beta gene polymorphism and the susceptibility of pancreatic cancer. Methods: A case-control study was conducted in China, including 58 pancreatic cancer cases and 156 healthy controls. Human genomic DNA was used as the template, polymerase chain reaction (PCR) was used to detect the distribution of LAPTM4B genotype. Analyses Odds ratio (OR) and corresponding 95% confidence interval (95%CI) with logistic regression were performed. Results: Two alleles of LAPTM4B generated three kinds of genotypes in population, *1/1, *1/2, and *2/2. The genotype frequency of *1/1, *1/2 and *2/2 in the pancreatic cancer group were 41.4%, 44.8% and 13.8% respectively, which were not significantly different from those of healthy group (47.4%, 42.9%, 9.6%) (P=0.773, P=0.291). Also the *2 allele frequency of LAPTM4B among pancreatic cancer had no significantly difference with the controls (P=0.354). When compared to the *1 allele, the people with *2 allele had no increased risk of pancreatic cancer. Conclusion: The gene polymorphism of LAPTM4B may not influence the susceptibility of pancreatic cancer. Objective: Lysosome associated protein transmembrane 4 beta (LAPTM4B) was originally identified as a gene in human hepatocellular carcinoma (HCC). It was successfully cloned by fluorescence differential display, rapid amplification of cDNA ends (RACE) and reverse transcription polymerase chain reaction (RT-PCR). Previous study showed that the novel gene played an important role in the occurrence, development, migration and prognosis of tumors. Pancreatic cancer is an aggressive malignancy with the majority of patients dying within one year after diagnosis. This study tries to find out the relationship between lysosome associated protein transmembrane 4 beta gene polymorphism and the susceptibility of pancreatic cancer. Methods: A case-control study was conducted in China, including 58 pancreatic cancer cases and 156 healthy controls. Human genomic DNA was used as the template, polymerase chain reaction (PCR) was used to detect the distribution of LAPTM4B genotype. Analyses Odds ratio (OR) and corresponding 95% confidence interval (95%CI) with logistic regression were performed. Results: Two alleles of LAPTM4B generated three kinds of genotypes in population, *1/1, *1/2, and *2/2. The genotype frequency of *1/1, *1/2 and *2/2 in the pancreatic cancer group were 41.4%, 44.8% and 13.8% respectively, which were not significantly different from those of healthy group (47.4%, 42.9%, 9.6%) (P=0.773, P=0.291). Also the *2 allele frequency of LAPTM4B among pancreatic cancer had no significantly difference with the controls (P=0.354). When compared to the *1 allele, the people with *2 allele had no increased risk of pancreatic cancer. Conclusion: The gene polymorphism of LAPTM4B may not influence the susceptibility of pancreatic cancer.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2010年第4期291-295,共5页 中国癌症研究(英文版)
基金 supported by the National Natural Science Foundation of China(No. 81071422)
关键词 Polymorphism Lysosome associated protein transmembrane 4 beta Pancreatic cancer SUSCEPTIBILITY Polymorphism Lysosome associated protein transmembrane 4 beta Pancreatic cancer Susceptibility
  • 相关文献

参考文献2

二级参考文献38

  • 1Parkin DM, Muir CS. Cancer Incidence in five continents.Comparability and quality of data. IARC Sci Publ 1992; 45-173.
  • 2Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19:271-285.
  • 3Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32(1 Suppl): 225-237.
  • 4EI-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. New Engl J Med 1999; 340:745-750.
  • 5Kaczynski J, Oden A. The rising incidence of hepatocellular carcinoma. N Engl J Med 1999; 341:451.
  • 6Ince N, Wands JR. The increasing incidence of hepatocellular carcinoma. N Engl J Med 1999; 340:798-799.
  • 7Benhamiche AM, Faivre C, Minello A, Clinard F, Mitry E,Hillon P, Faivre J. Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995. I Hepatol 1998; 29:802-806.
  • 8Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29:1596-1601.
  • 9Mant JW, Vessey MP. Trends in mortality from primary liver cancer in England and Wales 1975-1992: influence of oral contraceptives. Br J Cancer 1995; 72:800-803.
  • 10Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK 1979-1994.Lancet 1997; 350:1142-1143.

共引文献22

同被引文献8

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部